Abstract
Unfortunately, antiepileptic drug therapy fails to control seizure activity in a relevant percentage of epilepsy patients. Epidemiological data as well as findings in human epileptic tissue and in rodent models indicate that drug resistance is a multi-factorial phenomenon with various factors contributing to therapeutic failure. Enhanced efflux transport of antiepileptic drugs as a consequence of seizure-associated up-regulation of transporters such as P-glycoprotein constitutes one factor discussed in this context. Evidence exists that expression rates of P-glycoprotein correlate with drug response in rodent models and in patients. Moreover, add-on of a Pglycoprotein modulator proved to be efficacious in a rat model of drug-resistant epilepsy.
Further proof is obviously needed regarding the relative functional relevance of blood-brain barrier efflux for antiepileptic drug efficacy in epilepsy patients. Ongoing studies with positron emission tomography using transporter substrate radiotracers might provide further information. However, these studies also face major challenges considering the complexity of various factors affecting the kinetics of radiotracers in central nervous system pathologies.
Keywords: Seizure, blood-brain barrier, transporter, drug resistance, p-glycoprotein.
Current Pharmaceutical Design
Title:CNS Transporters and Drug Delivery in Epilepsy
Volume: 20 Issue: 10
Author(s): Heidrun Potschka and Hiram Luna-Munguia
Affiliation:
Keywords: Seizure, blood-brain barrier, transporter, drug resistance, p-glycoprotein.
Abstract: Unfortunately, antiepileptic drug therapy fails to control seizure activity in a relevant percentage of epilepsy patients. Epidemiological data as well as findings in human epileptic tissue and in rodent models indicate that drug resistance is a multi-factorial phenomenon with various factors contributing to therapeutic failure. Enhanced efflux transport of antiepileptic drugs as a consequence of seizure-associated up-regulation of transporters such as P-glycoprotein constitutes one factor discussed in this context. Evidence exists that expression rates of P-glycoprotein correlate with drug response in rodent models and in patients. Moreover, add-on of a Pglycoprotein modulator proved to be efficacious in a rat model of drug-resistant epilepsy.
Further proof is obviously needed regarding the relative functional relevance of blood-brain barrier efflux for antiepileptic drug efficacy in epilepsy patients. Ongoing studies with positron emission tomography using transporter substrate radiotracers might provide further information. However, these studies also face major challenges considering the complexity of various factors affecting the kinetics of radiotracers in central nervous system pathologies.
Export Options
About this article
Cite this article as:
Potschka Heidrun and Luna-Munguia Hiram, CNS Transporters and Drug Delivery in Epilepsy, Current Pharmaceutical Design 2014; 20 (10) . https://dx.doi.org/10.2174/13816128113199990461
DOI https://dx.doi.org/10.2174/13816128113199990461 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Design, Synthesis and Protection Against Pentylenetetrazole-induced Seizure of N-aryl Derivatives of the Phthalimide Pharmacophore
Medicinal Chemistry QSAR Studies on some Calcium Channel Blockers
Letters in Drug Design & Discovery Targeting Oxidative Stress Component in the Therapeutics of Epilepsy
Current Topics in Medicinal Chemistry Intracerebrally Applied Botulinum Neurotoxin in Experimental Neuroscience
Current Pharmaceutical Biotechnology The NMDA Receptor NR2B Subunit: A Valid Therapeutic Target for Multiple CNS Pathologies
Current Medicinal Chemistry Current Quest in Natural Bioactive Compounds for Alzheimer’s Disease: Multi-Targeted-Designed-Ligand Based Approach with Preclinical and Clinical Based Evidence
Current Drug Targets Psychobiological Model of Personality: Guidelines for Pharmacotherapy of Personality Disorder
Current Psychopharmacology Recent Advances on the Possible Neuroprotective Activities of Epstein- Barr Virus Oncogene BARF1 Protein in Chronic Inflammatory Disorders of Central Nervous System
Current Neuropharmacology To Analyze the Amelioration of Phenobarbital Induced Oxidative Stress by Erucin, as Indicated by Biochemical and Histological Alterations
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Potential of Natural Products from Terrestrial Plants as TNF-α Antagonist
Current Topics in Medicinal Chemistry Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Warfarin Dosing and the Promise of Pharmacogenomics
Current Clinical Pharmacology Medical Technology: A Systematic Review on Medical Devices Utilized for Epilepsy Prediction and Management
Current Neuropharmacology Oxidative/Nitrosative Brain Damage in Stress: Possible Target for Neuropsychopharmacological Drugs
Current Medicinal Chemistry - Central Nervous System Agents New Adamantane Derivatives with Sigma Affinity and Antiproliferative Activity
Medicinal Chemistry Neural Stem Cell Niches in Health and Diseases
Current Pharmaceutical Design Assessment and Imaging of the Cerebrovascular Glycocalyx
Current Neurovascular Research MicroRNAs: Key Players in Microglia and Astrocyte Mediated Inflammation in CNS Pathologies
Current Medicinal Chemistry Crosstalk between Gut Microbiota and Central Nervous System: A Focus on Alzheimer's Disease
Current Alzheimer Research Neuroprotective Effects of Drug-Induced Therapeutic Hypothermia in Central Nervous System Diseases
Current Drug Targets